Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal ...

This effect was not observed when MARCO was targeted alongside anti-PD1 therapy, emphasizing the ... regression and immune ...

A new review published in Genes & Diseases highlights macrophage-targeted therapy as a promising frontier in cardiac ...

After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...

Cellis has created its macrophage–drug conjugate (MDC) platform to overcome the challenges. “The MDC platform presents a highly novel cell-therapy approach that can be delivered in an ...

The macrophages also showcased morphological changes. “Looking at the world of cancer immunology and cell therapy, it is largely driven by biology. However, in addition to the biology of the cell, it ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

As of early 2025, tuberculosis cases are increasing in the U.S. This disease, often shortened to TB, causes significant lung damage and, if not treated, is almost always lethal.

Researchers have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor ... of immunotherapy known as anti-CTLA4 therapy, significantly enhances tumor ...

Greenwich Lifesciences Inc. followed a February update with another on the phase III Flamingo-01 trial, providing open-label immune response data for GLSI-100, a HER2/neu peptide vaccine immunotherapy ...